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 ABSTRACT 
Chronic obstructive pulmonary disease (COPD), the fourth leading cause of death worldwide, 
is characterized by persistent airflow limitation and a chronic inflammation of the lungs. One 
of the major risk factors is long-term exposure to cigarette smoking. The key inflammatory 
cells in the pathogenesis of COPD are macrophages, neutrophils and CD8+ T lymphocytes.  
The heterogeneity of COPD and the need for identifying patient subgroups is becoming 
increasingly recognized. Besides, the differences in the immunopathology of current- and ex-
smokers with COPD are uncertain. Characterizing the inflammatory mechanisms driving the 
disease in different subtypes of patients, including differences between men and women, will 
likely aid diagnostic procedures and tailoring of treatment strategies and caretaking.  
To investigate the airway and systemic inflammatory profile and the role for T cells in 
smoke-induced inflammation and COPD, bronchoalveolar lavage (BAL) fluid, blood and 
chest high resolution computed tomograpthy (HRCT) scans were collected from a gender- 
and age-matched cohort of 40 never-smokers, 40 smokers with normal lung function and 38 
COPD patients (27 current smokers and 11 ex-smokers). BAL characteristics, including the 
distribution of inflammatory cells, were assessed. T cells subsets in BAL and blood were 
phenotyped using flow cytometry, and the levels of cytokines, chemokines and growth 
factors in BAL fluid were assessed with a multi-plex bead-based assay. HRCT images of the 
lungs were analyzed for the investigation of morphological patterns and correlated with the 
cellular inflammatory patterns of the lungs. In addition to univariate analysis, multivariate 
data analysis with OPLS-modeling was used for discovering within- and between group 
variations, and potential biomarkers. 
The frequencies of several T cell subsets, including CD8+ T cells and NKT-like cells, both 
with cytotoxic capacities, and CD103+CD8+ T cells, were increased in BAL from smokers, 
regardless of airway obstruction. In COPD ex-smokers, the levels were similar to those of 
never-smokers. A more detailed phenotypic characterization of T cells revealed subsets 
specifically altered in smokers with normal lung function or COPD patients, including 
FOXP3+ regulatory T cells. A type 1 T cell-driven inflammation was indicated for female, 
but not male, COPD patients. Lung density, as measured by HRCT, was higher in smokers 
compared to both never-smokers and COPD patients and correlated with the cellular 
inflammation in the lungs. 
Taken together, these findings suggest that current smoking status has a larger impact on the 
distribution of lymphocytes in BAL than does airway obstruction. A detailed characterization 
of T cell subsets is important for finding disease-specific alterations. Gender-specific 
differences among smokers and COPD patients can be detected on a cellular level. 
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1 THE IMMUNE SYSTEM 
The immune system defends the body against invading pathogens such as bacteria and 
viruses, as well as tumor cells, toxic substances and pollutants.  
An inflammatory response against infection or irritation is detrimental to the invader but can 
also cause more harm than good to the host if the response causes excessive damage or 
become persistent. It is vital that the complex series of pathways of the immune system 
response are tightly controlled. Disruption of the inflammatory response can cause inhibition 
of immune cell activation with an increased susceptibility to infection. However, immune 
system dysfunction can also lead to excessive activation as seen in various inflammatory 
diseases. 
The immune system is typically divided into two distinct but interdependent categories: the 
innate and the adaptive immune system (Figure 1). The innate immunity, also known as the 
non-specific immunity, is the first line of defense and is composed of cells and mechanisms 
that can respond rapidly to a potential threat. The adaptive immunity is a more complex 
process where antigens (in some cases presented by cells of the innate immunity) are 
specifically recognized by cells of the adaptive immunity. This mounts a response to antigen 
including long-lasting memory protecting the host to subsequent encounter [1]. 
 
  
Figure 1. Cells of the innate and adaptive immune system. 
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1.1 THE INNATE IMMUNE SYSTEM 
The cells and mediators of the innate immune system are the first line of defense against 
invasion and can act immediately or within hours after recognizing a potential threat. The 
major functions of the innate immune system include non-specific recognition of a pathogen, 
induction of the adaptive immune system and regulation of the adaptive immune system. 
Epithelial barriers, humoral factors such as antimicrobial peptides and complement proteins 
that can recognize pathogens, and cells of the innate defense, accomplish this. Innate immune 
cells are present in all tissues and include: macrophages, dendritic cells, monocytes, 
neutrophils, natural killer (NK) cells and mast cells [1, 2]. 
Neutrophils and monocytes (after differentiation into macrophages at the site of 
inflammation) are specialized in capturing and ingesting pathogens and cells in search for 
potential harms, a mechanism called phagocytosis. As pathogens, or parts thereof, are 
recognized by the receptors on phagocytes, the cells become activated to produce a range of 
pro-inflammatory cytokines and chemokines that activate and direct other parts of the 
immune system. Through their role as antigen presenting cells (APCs), macrophages 
introduce antigens to the T cells of the adaptive immune system. Furthermore, they ingest 
apoptotic cells before they lyse thereby preventing the release of potentially harmful 
substances into surrounding tissue. Dendritic cells are also phagocytes and are present in 
tissues in direct contact with the external environment such as skin and the airways. They are 
important APCs linking the innate and adaptive immune systems, since they are responsible 
for the initial activation of T cells. Phagocytes express pattern recognition receptors (PRRs) 
that recognize conserved structures shared by many pathogens named pathogen-associated 
molecular patterns (PAMPs). PRRs can also respond to endogenous molecules that are 
released after cell damage known as damage-associated molecular patterns (DAMPs). Most 
infections are cleared by the innate immune system, but persistent infections require a more 
complex defense. Together with the dendritic cells, NK cells can initiate and direct the 
adaptive immune system, forming a link between innate and adaptive immunity. The NK 
cells share characteristics of both innate and adaptive immune cells. They are classified as 
lymphocytes based on their origin as lymphoid progenitors, expression of lymphoid markers 
and morphology, but are considered components of the innate immune system due to the 
absence of antigen-specific cell receptors on their surface [1, 3]. 
 
1.2 THE ADAPTIVE IMMUNE SYSTEM  
In contrast to the innate immune response, the T- and B lymphocytes of the adaptive immune 
system have a much higher specificity for antigens and can provide an efficient defense able 
to remember and store information for a quick and increased protection at a subsequent 
encounter with the same antigen.  
Lymphocytes express antigen-specific receptors that recognize specific protein structures and 
amino acid sequences from the processed antigen. Antigen-specific naive lymphocytes 
continuously pass through the lymphoid tissues and organs. If the meet and interact with a 
target cell displaying that specific antigen, they become primed and respond by 
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differentiation and cell division, generating an army of immune effector cells of the same 
specificity, designed to eliminate the antigen. On the first encounter with an antigen, it can 
take up to a week before the response becomes protective. After pathogen clearance, most 
antigen-specific B- and T cells undergo apoptosis. However, some cells remain and 
differentiate into memory cells that can mount a more rapid and effective immune response 
when re-encountering the same antigen [4]. 
B cells originate and mature in the bone marrow and mediate humoral immune responses. 
They express antigen-specific B cell surface receptors and after encountering their antigen, 
the cells start to proliferate and differentiate into plasma cells that secrete antibodies. 
Antibodies can neutralize toxins and opsonize pathogens in the extra-cellular compartments. 
T cells on the other hand provide cell-mediated immune responses. They also originate in the 
bone marrow but then migrate as immature thymocytes to the thymus, where they mature.  
CD4+ T helper (Th) cells are activated by extracellular antigens presented by major 
histocompatibility complex (MHC) class II molecules on APCs (B cells and DCs) to help 
orchestrate specific immune responses through the secretion of cytokines [5]. For instance, 
they help boost the effector functions of macrophages so they more efficiently can kill 
ingested pathogens. 
CD8+ T (Tc) cytotoxic cells recognize intracellular antigens such as viral antigens presented 
by MHC class I on APCs [5]. The CD8+ T cells, as well as NK cells, kill infected cells 
directly, either through membranolysis or by the Fas ligand/Fas system. The pathway of 
membranolysis is mediated by the release of perforin that forms pores in the cell surface of 
the target cell, and the subsequent entry of granzymes that activate cell-death pathways 
resulting in rapid death of the target cell. The alternative cell death pathway involves the 
engagement of FAS (death) receptors on the target cell and the FAS ligand on the killer cell, 
resulting in caspase-dependent apoptosis [6].  
 
1.2.1 Regulatory T cells 
T regulatory cells (Tregs) prevent autoimmunity and also control inflammation during 
protective immune defenses to prevent tissue damage. They exert their immunoregulatory 
actions through different mechanisms; by producing the immunosuppressive cytokines 
transforming growth factor (TGF)-β and interleukin (IL)-10, modulating APC maturation and 
function, depleting effector T cells and by disrupting metabolic pathways [7, 8]. 
The two most studied subsets of regulatory T cells are the natural Tregs and the induced 
Tregs. Both subsets derive from the thymus and circulate in the periphery as differentiated 
CD4+ T cells expressing the transcription factor Forkhead box P3 (FOXP3). Natural Tregs 
differentiate in the thymus and migrate to the periphery as CD4+CD25+FOXP3+ T cells 
where they act to maintain self-tolerance. Induced Tregs differentiate in the secondary 
lymphoid organs and tissues following antigen-presentation by DCs, in the presence of 
cytokines such as TGF-β and IL-10 [9, 10]. Later, other subsets of regulatory T cells have 
been identified, including CD8+ regulatory T cells [11]. 
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The study of Tregs is hampered by the lack of specific and reliable phenotypic markers. 
Accumulating evidence suggests that FOXP3 and CD25, as well as other currently used Treg 
markers (CTLA-4 and absence of CD127 for example) are not strictly specific for Tregs but 
are also T cell activation markers [8]. 
 
1.2.2 Chemotactic T cell recruitment and the Th1/Th2 balance  
Chemokines are small cytokines that induce recruitment of leukocytes through specific 
binding to chemokine receptors. Chemokines and their receptors are key players in the 
immune defense through their chemotactic and immunoregulatory actions. Recruitment of 
leukocytes to sites of infection and/or inflammation is essential for the host defense but might 
also contribute to disease by maintaining and amplifying chronic inflammation. 
The nomenclature of chemokines and chemokine receptors is based on the number and 
spacing of the conserved cysteine residues at the amino terminus of the protein. Among four 
different families of chemokines, members of the family of CXC chemokines have an 
intervening non-conserved amino acid between the first two cysteines, whereas members of 
the CC chemokine family have two adjacent cysteines [12]. 
T cells can be divided into functionally distinct subsets based on the cytokines they produce, 
the most traditional being Th1/Tc1 and Th2/Tc2, but later additional subsets were discovered 
including Th17, Th22 and Th9 [13]. Moreover, the T cell subsets express a distinct set of 
chemokine receptors specific for only a few chemokines [14, 15]. 
Th1/Tc1 cells produce IFN-γ, TNF and IL-2. They regulate cellular immunity and antigen-
specific presentation, as well as stimulate macrophages, recruit inflammatory cells to the site 
of inflammation and act on B cells to stimulate antibody class switching. Th1/Tc1 cells are 
recruited to the site of inflammation via their chemokine receptors CXCR3 and CCR5, which 
bind to the chemokines CXCL9-11 and CCL3-4 respectively. 
Th2/Tc2 cells produce IL-4, IL-5 and IL-13 and regulate humoral immunity and allergy. 
Th2/Tc2 cells are recruited through the binding of CXCL12 to the chemokine receptor 
CXCR4 [14-16]. 
5  
2 THE RESPIRATORY SYSTEM 
The respiratory system includes air passages, the lungs and pulmonary vessels. The main 
function is to supply the body with oxygen from the inspired air and remove carbon dioxide 
from the circulation. When breathing, air first enters through the nose or mouth, passes 
through the nasal cavities and continues down the trachea. As the trachea divides into two 
primary bronchi, each entering one of the two lungs, the air reaches the airway branching of 
increasingly smaller bronchi. The smallest airways, bronchioles, end up in the tiny air sacs 
called alveoli. In the alveolar walls, a network of capillaries allow for efficient exchange of 
oxygen and carbon dioxide between the air and the blood stream (Figure 2) [17]. 
 
The airway epithelium represents the first line of defense of the lung against airborne harmful 
agents, which include pathogens, toxins and pollutants. In addition to the epithelium 
providing a physical barrier, ciliated cells and mucus producing goblet cells lining the 
epithelium enable mucociliary clearance of the foreign particles out of the airways through 
the cough reflex. Upon recognition of threats, the airway epithelium activates innate and 
adaptive immune mechanisms. This includes production of antimicrobial substances as well 
as pro-inflammatory cytokines and chemokines that recruit and activate more inflammatory 
cells into the airway lumen [18, 19].  
Figure 2. The bronchial tree of the lung and the alveoli covered by a network of capillaries. 
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3 CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
The global initiative for chronic obstructive lung diseases (GOLD) defines COPD as follows: 
"Chronic obstructive pulmonary disease (COPD), a common preventable and treatable 
disease, is characterized by persistent airflow limitation that is usually progressive and 
associated with an enhanced chronic inflammatory response in the airways and the lung to 
noxious particles or gases. Exacerbations and comorbidities contribute to the overall severity 
in individual patients" [20]. 
The most common symptoms are shortness of breath and chronic cough. In addition, patients 
with COPD may experience extrapulmonary effects such as cardiovascular and psychological 
conditions [21]. An underlying inflammatory process, most often caused by exposures to 
noxious particles and gases, is believed to drive the disease progress. 
 
3.1 EPIDEMIOLOGY AND RISK FACTORS 
COPD is one of the leading causes of morbidity and mortality worldwide representing an 
extensive economic and social burden [22, 23]. The disease is currently the 4th leading cause 
of death affecting over 200 million people [24] and estimates show, that by 2030 it will be the 
third leading cause of death [22]. However, COPD-related prevalence and mortality is most 
likely underestimated as most information available comes from high-income countries and 
the vast majority of COPD deaths are believed to occur in low- and middle-income countries. 
COPD has historically been considered a men's disease, but the prevalence as well as the 
hospitalization and mortality rates, of women have now surpassed men [25]. Women seem to 
be more susceptible to the toxic effects of cigarette smoking [26]. 
In the industrialized world, the major cause of COPD is tobacco smoking. However, not all 
smokers develop COPD, indicating that the disease development also is related to genetic 
predispositions. Other risk factors for developing the disease are increasingly being 
recognized. These include inhalation of other toxic particles and gases through outdoor air 
pollution, occupational dusts and chemicals, and indoor air pollution from the burning of 
biomass fuels used for cooking and heating in developing countries [2, 27]. Additional causes 
of COPD include passive exposure to cigarette smoke, deficiency of alpha1-antitrypsin [28] 
and impaired lung growth in early life [29]. In the current thesis, the focus is on COPD 
caused by cigarette smoking. 
 
3.2 PATHOPHYSIOLOGY 
The most common symptoms of COPD are dyspnea, chronic cough and sputum production. 
Primarily two distinct features are responsible for the pathogenesis of the disease and they 
often coexist; the obstruction of the peripheral airways and the emphysematous destruction of 
the alveoli [30].   
3.2.1 Bronchiolitis 
The major site of obstruction in COPD is the smaller airways of less than 2 mm in internal 
diameter. In the response to repetitive tissue damage from long-term smoking, inflammatory 
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repair and remodeling mechanisms result in bronchial wall thickening. The toxic smoke also 
increases mucus production with concurrent luminal plugs. The increased airway resistance 
in bronchiolitis is thus a combined effect of the remodeling and mucus secretion. 
3.2.2 Emphysema 
In emphysema, destruction of alveolar walls forms permanent enlargements of the alveoli, 
resulting in a reduced gas exchange and air trapping, with a decrease in expiratory flow rates  
(Figure 3). Importantly, emphysematous destruction of the lung elastic recoil results in 
impaired exhalation, which may result in a buildup of carbon dioxide [31].   
Figure 3. Alveoli in normal lungs (left) and in lungs with emphysema (right). Credit: NIH. 
 
3.2.3 Chronic bronchitis  
Chronic bronchitis is a common feature in smokers and COPD patients. It is a clinical 
diagnosis characterized by inflammation of the bronchial tubes giving rise to excessive 
mucus production and chronic cough (Figure 4). There are a number of clinical consequences 
for COPD patients with chronic bronchitis, including accelerated reduction in lung function, 
higher risk for acute worsenings of the disease and increased risk of mortality [32-34].  
 
Figure 4. Normal bronchial tube and bronchial tube with bronchitis, characterized by  
  an inflamed wall and increased amount of mucus. 
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3.2.4 Comorbidities  
Comorbid conditions such as cardiovascular disease, cancer, osteoporosis and depression are 
common in COPD. The relationships between these are uncertain and are believed to involve 
an immune-mediated link between the lungs and circulation. Evidence for this include studies 
showing significantly elevated levels of several systemic inflammatory markers, such as 
circulating leukocytes, C-reactive protein and TNF-α, in COPD. The comorbidities are often 
detrimental, as they can interfere with the COPD management, affect the patient's health 
status and accelerate the worsening of the disease [35, 36]. 
 
3.3 CLINICAL FEATURES 
3.3.1 Diagnosis 
Diagnosis of COPD is based on the presence of airflow obstruction, which is assessed with 
spirometry. The essential values of spirometry for COPD diagnosis are the forced expiratory 
volume in 1 second (FEV1) and the forced vital capacity (FVC). FEV1 is the volume of air 
expired in the first second during maximal expiratory effort and is reduced in obstructive lung 
disease because of increased airway resistance. FVC is the total volume of air expired after a 
full inspiration. In patients with obstructive lung disease, FEV1/FVC is decreased compared 
to healthy and a post-bronchodilator ratio of FEV1/FVC below 0.7 confirms the presence of 
chronic airflow limitation. Most often, the value of FEV1 used for an individual is FEV1% 
predicted, which is derived after correcting for the average FEV1% in the population for any 
person of similar age, sex and body composition. 
COPD is classically divided into four stages of severity based on spirometric cut-off values 
for FEV1, according to GOLD [20] (Table 1). Stage I (mild) is characterized by mild airflow 
limitation, and possibly symptoms like cough or mucus production. However, the patient may 
not suffer from any symptoms and may therefore be unaware of the disease. At stage II 
(moderate), airflow limitations are worsening and symptoms include shortness of breath. 
Stage III (severe) and IV (very severe) involve severe airflow limitation and substantially 
impaired quality of life [37].  In recent years, the impact of symptoms, exacerbation 
frequencies and co-morbidities on disease severity have been acknowledged, and included in 
the assessment of COPD [20]. 
Table 1. Degrees of disease severity in COPD based on spirometry values according to GOLD [20]. 
Basal criterion for all stages: FEV1/FVC < 0.7 
Stage  FEV1 % of predicted 
I Mild ≥80 
II Moderate  50 to <80 
III Severe 30 to <50 
IV Very severe <30 
Based on postbronchodilator values. FEV1: forced expiratory volume in 1 second; FVC: forced vital 
capacity.  
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3.3.2 Treatment 
To date, smoking cessation is the most important measure for increased survival in COPD. 
Besides smoking cessation, and the use of supplemental oxygen in selected patients, no 
efficacious treatments currently exist to treat or prevent the progression of COPD. Current 
pharmacological treatments can only relieve the symptoms and complications but do not 
eliminate the underlying inflammatory process. This underlines the need for a greater 
understanding of the cellular and molecular mechanisms of COPD and the identification of 
biomarkers in the search for novel therapies. As subcategories of COPD patients more 
susceptible to certain treatments exist, for example those with some reversibility after b2-
agonsists [38], identifying patient phenotypes may be needed for customized treatment.  
 
3.4 IMMUNE PATHOLOGY IN COPD 
Long-term, cumulative exposure to the noxious particles and gases in cigarette smoke triggers 
an inflammatory process, and in some predisposed individuals this leads to the development 
of COPD. Compared to the response to cigarette smoke in individuals without lung disease, 
COPD patients have developed an abnormal chronic inflammatory process in the lungs. The 
pathology and clinical course of COPD is the result of complex interactions between the cells 
of the innate and adaptive immune system (Figure 5) [2].  
 
 
Figure 5. The proposed immune process underlying the pathogenesis of COPD. Reproduced from [2] with 
permission from The Lancet. 
In response to inhalation of toxicants, epithelial cells and macrophages become activated. 
Macrophages are attracted into the alveolar lumen, engulfing smoke particles and secreting 
matrix metalloproteinases involved in tissue destruction. Moreover, epithelial cells and 
macrophages release several chemotactic factors that attract monocytes, neutrophils and 
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T lymphocytes from the periphery. Dendritic cells activate and orchestrate adaptive immune 
responses of T cells and B cells. CD8-positive T cells accumulate in the airways and lung 
parenchyma of COPD lungs [39-42]. These cells, as well as NK cells and NKT-like cells, are 
able to destroy lung parenchyma through their cytolytic activities [6, 43]. CD4+ T cells 
increase in the lung in more severe stages of the disease and in emphysema [44, 45], where 
they recruit and activate other immune cells, including neutrophils, perpetuating the sustained 
inflammatory process. As T cells respond following antigen recognition, they differentiate in 
response to the inflammatory milieu to mount a response with a specific cytokine profile [2, 
30, 46, 47].  
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4 AIMS 
 
The overall aim of this thesis was to gain a better understanding of the characteristics of the 
inflammatory response in the lung and in the blood, to cigarette smoke exposure and in 
COPD, with emphasis on T cells. 
 
 
Specific aims were: 
 
 
Paper I 
To study major lymphocyte subsets and the differentiation status of T cells locally in the lung 
and systemically.  
 
 
Paper II 
To investigate the frequency and state of activation of intraepithelial (CD103+) T cells and 
the frequency of regulatory T cells in bronchoalveolar lavage (BAL) fluid and blood. 
 
 
Paper III 
To investigate if the morphological patterns of the lungs in response to cigarette smoking and 
in COPD, as shown by high resolution computed tomography (HRCT) images, associates 
with the cellular inflammation in the lung. 
 
 
Paper IV 
To elucidate which chemokines and chemokine receptors that may contribute to the 
recruitment of T cells to the lungs of smokers and patients with COPD and to characterize the 
Th1/Tc1 and Th2/Tc2 polarization in BAL fluid and blood and finally to relate the findings to 
clinical features, age and gender. 
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5 STUDY SUBJECTS AND METHODOLOGY 
5.1 STUDY SUBJECTS 
The studies in this thesis were carried out on subjects from the Karolinska COSMIC (COPD 
and Smoking from an OMIC Perspective (COSMIC) cohort at the Karolinska University 
Hospital Solna, Karolinska Institutet, Stockholm, Sweden. The aim of the COSMIC study is 
to investigate and integrate several aspects of COPD and smoking through imaging, 
transcriptomics, proteomics, metabolomics, and lymphocyte profiling in the context of 
clinical phenotypes [48-50]. A total of 40 never smokers, 40 smokers with normal lung 
function and 38 patients with COPD (GOLD I-II) with equal numbers of women and men 
were recruited with the intent to collect blood and bronchoalveolar lavage (BAL). Among the 
COPD patients, 27 were current smokers and 11 were ex-smokers, which had refrained from 
smoking for at least 2 years prior to the inclusion in the study. All subjects were matched in 
terms of age (45-65 years) and smokers and COPD patients were matched for smoking 
history. Detailed characteristics of the study subjects and BAL as well as exclusion criteria 
are described in paper I [51]. 
 
5.2 BRONCHOSCOPY WITH BRONCHOALVEOLAR LAVAGE 
Bronchoscopy is routinely used in the diagnostic procedure for several lung diseases, 
including COPD. A bronchoscope is inserted into the airways, usually through the nose or 
mouth, enabling the physician to investigate the pathology and inflammatory status of the 
airways. A small camera on the tip of the bronchoscope is used for viewing the airways. 
Besides, samples from the lower respiratory tract can be obtained from BAL and biopsies 
(Figure 6). 
Figure 6. Bronchoscopy with bronchoalveolar lavage. 
Bronchoscopy and BAL were performed according to a standard protocol at our clinic [52]. 
Briefly, a flexible fiberoptic bronchoscope was passed nasally and wedged into a middle lobe 
bronchus where five aliquots of 50 mL sterile saline solution were instilled and recollected, 
bringing back BAL fluid.  
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Cells were separated from the recovered BAL by centrifugation. Leukocyte differential cell 
counts were determined on cytospin slides prepared with native pellet and stained with May-
Grünwald Giemsa. The cell-free BAL was centrifuged to eliminate cell debris, and the 
supernatant was stored at -80°C until further use. Bronchial brush biopsies were collected 
during the bronchoscopy.  
 
5.3 HIGH RESOLUTION COMPUTED TOMOGRAPHY 
High resolution computed tomography (HRCT) imaging of the lungs is a non-invasive 
instrument for detailed visualization and quantification of the organ structure. It is used in the 
diagnosis of several lung diseases and has proven useful in the diagnosis of pulmonary 
emphysema [53]. CT attenuation values are expressed as Hounsfield units (HU), which have 
been arbitrarily chosen to 0 for water density and -1000 for air density. 
In paper III, CT examinations of the study subjects were performed. The main focus was the 
percentage of the lung parenchyma with attenuation between -750 and -900 HU (the high 
density spectrum, %HDS) to investigate how CT may reflect the enhanced inflammation in 
smokers. 
 
5.4 MULTICOLOR FLOW CYTOMETRY 
In paper I, II and IV, 8-color flow cytometric immunophenotyping of lymphocytes from BAL 
and whole blood was performed. Flow cytometry measures several characteristics of 
individual cells, in large numbers, as they pass through a laser beam under laminar flow 
conditions. Depending on how the laser beam is deflected, the size and granularity of the cell 
is assessed. The use of fluorescent-labeled monoclonal antibodies to surface or intracellular 
molecules gives detailed information on the type of cells in the sample.  
The majority of cells in BAL fluid are macrophages. Their phagocytosis of dust particles 
causes a strong autofluorescence that interferes with the fluorescent staining of the 
lymphocytes, used in flow cytometry. This is particularly a problem in BAL fluid from 
smokers where macrophages also phagocyte smoke particles. Alveolar macrophages have 
been shown to increase in number and cause a stronger autofluorescence in smokers [54]. 
Therefore, the first step after cell isolation from BAL fluid was to deplete the macrophages 
using carbonyl iron [55].  
Cells from blood and BAL fluid were stained with fluorescently labeled monoclonal 
antibodies in five different antibody panels, and samples were run on a FACSCanto II. Data 
were analyzed in FACSDiva 6.1.2. Representative flow cytometry dot plots from paper I are 
depicted in Figure 7. 
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Figure 7. In paper I, a multicolor test for analysis of lymphocytes was used and the distribution of CD8 
and CD4-positive T cells, natural killer (NK) cells and NKT-like cells, and B cells was assessed. NK 
cells and NKT-like cells were identified with a combination of monoclonal antibodies against both 
CD16 and CD56. 
 
5.5 MULTIPLEX MAGNETIC BEAD-BASED ASSAY 
In paper IV, BAL supernatants were concentrated using centrifugal filters and analyzed for 
chemokines, cytokines and growth factors (listed in paper IV) using multiplex magnetic 
bead-based assay based on Luminex® xMAP® technology. Multiplex data were analyzed 
using Bio-Plex Manager software, version 6.0 (Bio-Rad). Samples were run in duplicates. 
Data out of range or below lower limit of quantification (LLOQ), or sample with high 
technical variance (CV>50%) were excluded from all further analyses. Mean-centering and 
scaling to univariate variance was used to correct for batch effects. Strong intragroup outliers, 
as identified by Dixon's q-test (p<0.05), were excluded. 
 
5.6 UNIVARIATE DATA ANALYSIS 
Data are presented as median (range) in paper I, II and IV, unless otherwise stated. The 
Mann-Whitney U-test was used when two groups were compared. When more than two 
groups were analyzed, Kruskal-Wallis test followed by Dunn's multiple comparison test for 
non-parametric data were performed. A p-value <0.05 was considered statistically significant. 
Correlation analyses were assessed with Spearman's rank correlation test and in paper I, the 
resulting p-values were adjusted for multiple testing using the false discovery rate (FDR) 
according to Benjamini and Hochberg [56]. An FDR <0.05 was considered statistically 
significant. Statistical comparisons and graphs were performed in GraphPad Prism software, 
version 5.02. In paper III, data are presented as mean and SD. Stata12 software was used for 
statistical analysis (Stata Corp, College Station, TX, USA). 
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5.7 MULTIVARIATE DATA ANALYSIS 
The classical methods of univariate statistics can often be misleading as in reality; multiple 
factors can interact and influence the outcome. Today, as an increasing number of studies 
collect data consisting of variables, multivariate data analysis can be used to extract 
information from multiple variables by not only taking into account several predictors 
simultaneously but also co-variance, thereby modeling the property of interest with more 
accuracy. Multivariate data analysis reduces the dimensionality of the data to aid visualizing 
and interpreting the results (Figure 8) [57]. The multivariate analyses were performed with 
SIMCA P+ software version 13 or 14 (Umetrics AB, Umeå, Sweden) applying both 
unsupervised principal component analysis (PCA) and supervised orthogonal projections to 
latent structures (OPLS) analysis [58]. 
 
 
Figure 8. Illustration on how multivariate data analysis reduces the dimensionality of the data to help visualize and 
interpret the results. Reproduced from Wheelock and Wheelock [57]. Published by The Royal Society of 
Chemistry. 
 
5.7.1 Principal component analysis  
Principal component analysis (PCA) is an unsupervised method suitable for analysis of 
correlated modeling for a stronger visualization of data. The aim is to find a conversion of an 
original set of correlated variables to a reduced set of representative latent variables, called 
principal components [59]. PCA modeling provides an overview of trends in a dataset where 
correlations among observations and variables can be easily seen, as well as a method for 
quality control and outlier identification. 
 
5.7.2 Orthogonal projections of latent structures  
In orthogonal projections of latent structures (OPLS) analysis, two matrices of large data sets 
are connected, the X-block of predictor variables and the Y-block of response variables, with 
the objective to find the most applicable components of X that can predict Y. In contrast to 
the more commonly used PCA modeling, OPLS analysis is a supervised method designed to 
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separate structured noise of the X-block variables unrelated (orthogonal) to the predictive 
variance of interest (e.g. between patients and controls) and thereby increasing the 
interpretability of the multivariate model, particularly in deriving the observed group 
separation back to the variables of interest. The method can be used for discovering within- 
and between group variations, and may help identify potential biomarkers.  
In order to effectively evaluate the usefulness of an OPLS model, a number of model 
statistics are reported. The performance is reported as cumulative correlation coefficients for 
the model (R2) and predictive performance based on seven-fold cross validation calculations 
(Q2), as well as cross-validated ANOVA (CV-ANOVA) p-values for the OPLS models [57]. 
These are highly important, as a visually convincing separation does not always indicate a 
good model or a high predictive power. Over-fitting data may lead to an impressive graph 
showing a clear-cut separation of the groups, but without predictive or biological relevance. 
The scores- and loading plots in Figure 3 in paper IV shows an example of a score plot 
visualizing the separation of two groups of subjects and a loadings plot depicting the 
predominant response variables driving the separation. 
5.7.3 Shared and unique structure plot 
The results from individual OPLS models can be compared through shared and unique 
structures (SUS) analysis, where the scaled loadings (p[corr]) from two models are correlated 
(Figure 9). The resulting SUS-plot can be useful to identify biomarkers selective for a certain 
condition, or to find overlapping biomarkers of structures between two models [60]. 
 
Figure 9..SUS-plot comparing two models for the identification of COPD-specific responses. Response 
variables (e.g. proteins) unique for either model are found along the outer edges of the axes, specific for 
smokers in the green boxes and for COPD in the orange boxes. Alterations regardless of COPD diagnosis 
are located around the positive diagonal indicating that the variables in the blue boxes are not useful as 
COPD biomarkers. Similarly to univariate correlations, the closer to +1 and -1 the more reliable are the 
conclusions. Reproduced from Wheelock and Wheelock [ 49 ]. Published by The Royal Society of Chemistry. 
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6 RESULTS AND DISCUSSION 
6.1 CYTOTOXIC CELLS IN SMOKING AND COPD 
One of the most prominent findings in paper I was the increase in cells with cytotoxic 
capabilities in BAL fluid from current smokers. Regardless of airway obstruction, current 
smokers had higher proportions of CD8+ T cells (Figure 10) and NKT-like cells (defined as 
CD3+ and CD16+ and/or CD56+) in BAL than both never-smokers and ex-smokers with 
COPD. In addition, most NKT-like cells were CD8+ and there were higher proportions of 
NKT-like cells among CD8+ T cells, compared with never-smokers and ex-smokers. 
Increased proportions of NK cells were seen in smokers without COPD only.  
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Figure 10. Percentages of CD8+ T cells, and CD4+ T cells and the CD4/CD8 ratio in BAL and peripheral blood 
(PB) from never-smokers (NS), smokers (S), COPD smokers (CS) and COPD ex-smokers (CE) (paper I). 
 
A number of studies show increased numbers of cytotoxic cells (i.e. CD8+ T cells, NK cells 
and NKT-like cells) along with higher cytotoxic activity and increased production of perforin 
and granzyme, in different compartments of the lung, but not in blood, in COPD, [40, 43, 61-
63]. These cells are capable of causing the lung tissue destruction seen in COPD patients, 
both through cytokine secretion and via cytotoxic killing. Our results of a smoke-induced 
increase in CD8+ T cells, NK cells and NKT-like cells in BAL suggest an increased cytotoxic 
burden in the peripheral airways of smokers, even before they have developed COPD, that 
may contribute to the worsening of lung function. Functional studies are needed to investigate 
their role in smoke-induced inflammation of the lung. 
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The impact of current cigarette consumption on the proportions of cytotoxic T cells was 
further demonstrated by a positive correlation between the percentage of CD8-positive T cells 
in BAL from smokers with COPD and the number of cigarettes smoked per day during the 
preceding six months. This correlation was even stronger in male smokers with COPD 
(Figure 11). 
 
 
Figure 11. Correlation between the percentage of CD8+ T cells in BAL from male smokers with COPD and the 
number of cigarettes smoked per day during the preceding six months. p[FDR] = p-value corrected for multiple 
testing by means of false discovery rate according to Benjamin-Hochberg [56]; r = Spearman rank correlation 
coefficient (paper I). 
 
In paper II, T cells expressing the intraepithelial (CD103+) marker were investigated. The 
lymphocyte marker CD103 is the αE subunit of the αEβ7 integrin, which binds specifically to 
the adhesion molecule E-cadherin expressed in adherent junctions between epithelial cells. T 
cells expressing CD103 are selectively recruited and retained in mucosal tissues, and are 
named intraepithelial T cells. Previous studies have found that T cells accumulate in the 
airway epithelium, but prior to the publishing of paper II, their phenotype had not been 
investigated in more detail. We found higher percentages of CD103+ cells among the CD8+ 
T cells in BAL from both groups of smokers (Figure 12), suggesting a role for CD8+ T cells 
in the airway epithelium of smokers. As has been previously shown [64], the proportion of T 
cells expressing CD103 was higher in BAL than in blood. 
More recent findings have suggested that in addition to recruit and maintain T cells to the 
epithelium, CD103 can have other functions. It has been shown that CD103 can promote 
migration through epithelial cell layers [65], and has been proposed to be a marker for 
regulatory CD8+ T cells [66, 67].  
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Figure 12. Percentages of CD103-positive cells among CD4+ and CD8+ T cells in BAL and peripheral blood (PB) 
(paper II). 
 
An additional interesting finding in paper I was that proportions of activated CD69+ naive, 
central memory and effector CD4+ T cells often were the highest in BAL from smokers with 
COPD compared to the other three study groups. This shows that the combination of smoking 
and airway obstruction is related to activated T cell subsets, and that even though the total 
CD4 T cell number is unchanged, there may be important phenotypic changes. 
 
6.2 REGULATORY T CELLS 
Several studies suggest a decreased number and impaired function of regulatory T cells in 
COPD [68, 69]. We hypothesized that cigarette smoke affects the frequency of regulatory 
FOXP3+ T cells in the lung and that these changes also reflect development to COPD (paper 
II). CD4+ T cells from BAL fluid and blood were stained for FOXP3 to identify Tregs. 
Increased proportions of CD4+FOXP3+ T cells were found in BAL fluid from smokers 
compared with never-smokers (Figure 13). This upregulation was not seen among smokers 
with COPD. We reasoned that the increased frequency of Tregs in BAL from smokers with 
normal lung function has been central for their immune system's ability to counteract the 
 20 
continuous inflammatory burden, preventing the development of COPD. This finding may 
give a clue to why some smokers develop COPD and some not.  
 
 
Figure 13. Percentages of FOXP3+ CD4+ T cells in BAL fluid (paper II). 
 
As described above, CD103 can be a marker for regulatory T cells [67]. The CD4+FOXP3+ 
T cells described in paper II did not express CD103. When we analyzed the combination of 
the activation and differentiation markers CD69, CD27 and HLA-DR on CD103+ T cells 
(paper II), we found, within the CD8+CD103+ cells, a decrease in a subset of CD27+CD69- 
T cells with a lower HLA-DR expression in BAL from both groups of smokers. A subset of 
CD8+ T cells with, among others, these characteristics has previously been described as 
regulatory T cells that exert their suppressive functions via direct cell to cell-contact [67]. The 
decrease of this subset in the lungs of smokers might cause an increased susceptibility to 
persistent damage in the lung. 
Tregs play a critical role in regulating inflammatory responses, and a deficiency in function 
and/or numbers can lead to the development and progress of autoimmune and chronic 
inflammatory diseases [70, 71]. Autoimmunity is caused by insufficiently controlled B- and 
T-cell responses to self-antigens. Circulating antibodies to, among others, elastin and Hep-2 
epithelial cells have been shown to be increased in levels and more prevalent in COPD 
patients compared to controls [68, 72]. These and other findings suggest an autoimmune 
component in COPD pathogenesis, and may explain the enhanced and persistent 
inflammatory response after smoking cessation [73, 74]. 
 
6.3 HIGH RESOLUTION COMPUTED TOMOGRAPHY 
HRCT is a well-established method for morphological characterization of pulmonary 
emphysema [75]. Increased lung density on CT has been suggested to mirror inflammation in 
the lung parenchyma [76]. In paper III, CT images of the COSMIC study subjects were used 
for the quantification of inflammatory changes due to chronic smoking and in early stages of 
COPD. The lung density measurements focused on the attenuation range between  
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−750 and −900 HU (percentage higher density spectrum (%HDS)) on inspiratory CT-scans. 
Typical patterns seen on CT scans from a never-smoker, smoker and COPD patient are 
shown in Figure 14.  
 
Figure 14. Axial inspiratory CT scans of three 54 year old females, representing typical patterns for 
never-smokers (left), smokers (middle) and COPD patients (right) in this study (paper III). 
 
Lung density was higher in smokers with normal lung function compared to both never-
smokers and COPD patients (Figure 15). A possible explanation for the lack of differences 
between never-smokers and COPD patients may be that in the lungs of COPD patients, areas 
with decreased lung density (i.e. emphysema) and areas with increased lung density (i.e. 
accumulation of inflammatory cells) may occur in the same patient but in different regions of 
the lung. This would result in an average density of the lung comparable to a never-smoker's. 
CT imaging technique could be a valuable tool for the detection of early changes in the lungs 
of smokers. 
 
Figure 15. The relationship between lung densities measured as attenuation -750 HU to -900 HU (%HDS) for 
never-smokers, smokers and COPD patients (smokers and ex-smokers) (paper III). 
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6.4 T CELL RECRUITMENT TO THE LUNG 
In paper IV, factors important in the recruitment of T cells to the lung in smokers and COPD 
patients compared to never-smokers were investigated, and the cytokine milieu in BAL from 
these individuals was assessed. We especially focused on the Th1/Th2 balance. COPD is 
generally considered a Th1/Tc1-driven disease [2], but there are studies implicating a role 
also for Th2/Tc2 cells [77].  
In the present study, the Th1-associated chemokine receptor CCR5 was found to be more 
abundant on CD4+ T cells in BAL fluid from "healthy" smokers compared to never-smokers. 
This finding suggests a CCR5-mediated recruitment of CD4+ T cells to the lungs of smokers 
without COPD. We further show decreased levels of the Th2 cell cytokine IL-4 and the Th2-
associated chemokine CXCL12 in BAL fluid from both groups of smokers. Taken together, 
our findings show that a Th1/Tc1-biased inflammation is not solely related to COPD, but also 
to smoke-induced inflammation, particularly through the CCR5 chemokine receptor. 
Mapping out a more detailed picture of the T cell recruitment elements of importance in the 
development and progression and COPD may give rise to new treatment options targeting the 
chemokines and/or their receptors. 
Supervised OPLS-DA modeling comparing T cell subsets and soluble analytes of smokers 
with normal lung function versus smokers with COPD was performed in order to separate 
COPD-related factors from the dominating effects of smoking. Analysis of women and men 
separately revealed gender differences in the immune processes in COPD. Whereas a strong 
discrimination was found between smoking women with and without COPD (R2=0.50, 
Q2=0.41, p=8x10-4) with eleven variables indicated as driving the separation between the two 
groups, a less robust model was found among men (R2=0.32, Q2=0.25, p=0.016).  
The findings of a strong model for women, but not men, when comparing smokers without 
COPD to smokers with COPD support previous findings on the BAL cell proteome from the 
COSMIC cohort [49]. Our results indicate gender-specific molecular differences in the 
inflammatory response to cigarette smoke and in COPD. It can be speculated that compared 
to women, men with COPD is a more heterogeneous groups with a higher number of patient 
phenotypes. 
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7 CONCLUSIONS AND FUTURE PERSPECTIVES 
Besides smoking cessation, current treatment methods for COPD patients include 
bronchodilators and corticosteroids, but these do not act on the underlying inflammation. A 
number of treatments targeting the inflammatory process have been developed, but these do 
not cure the disease. Understanding the molecular and cellular patterns behind the 
inflammatory mechanisms, and their expression in subgroups of patients, is important for the 
development of biomarkers and new therapeutic interventions. 
As shown by others and us, the inflammatory process in smokers with normal lung function 
and smokers with COPD show both shared and unique characteristics, and many still remain 
unclear. The impact of current smoking status on CD8+ T cells in BAL that we present in 
paper I, is not reflected in biopsies from the small and large airways, as well as from the lung 
parenchyma, where increased numbers of CD8+ T cells seem related to COPD only. 
This thesis shows, that smoking largely determines the distribution of T lymphocyte subsets 
in the bronchoalveolar compartment and, however to a smaller extent, in the periphery. 
Several findings in the included papers revealed a similar characteristic; frequencies of T cell 
subsets were altered in the same fashion in smokers regardless of airway obstruction. In 
COPD ex-smokers, the frequencies had returned to those of never-smokers. This highlights 
the importance of studying present smokers and ex-smokers among COPD patients separately 
when investigating T cell subsets in BAL and blood. 
Even after smoking cessation, a continuous inflammatory process in the lungs of COPD 
patients is seen. A role for the adaptive immunity with the involvement of T lymphocytes has 
been suggested, particularly reflected in the lung tissue. Based on the findings in the papers 
included in this thesis, studies on T cells in BAL fluid requires detailed phenotyping to 
identify those cells reflecting early pathological changes in the lung. Comparisons of lung 
tissue biopsies and BAL fluid, ideally from the same individual, would give more 
information. Functional studies on the different T cells subsets, such as assessing their 
cytolytic capacity, could give a greater understanding of their role in the disease course.   
The heterogeneity of COPD is becoming increasingly recognized. Identifying subtypes of 
patients, characterized by e.g. genetic, immunological or clinical factors, can lead to a more 
tailored or individualized treatment. With increasing amounts of data collected and large 
study cohorts of well-characterized individuals, multivariate data analysis provides a means 
for extracting and integrating the many variables measured, for the identification of 
biomarkers and subgroups of patients. 
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